Smac Mimetic LCL161

Phase 2Small molecule

MM.D. Anderson Cancer Center

Smac Mimetic LCL161 is one of 36 small molecule programs targeting Primary Myelofibrosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Primary MyelofibrosisActive, not recruiting

Multiple MyelomaActive, not recruiting

Primary MyelofibrosisPhase 2

Active, not recruiting

Multiple MyelomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1135 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Prolia

Amgen

Preclinical

5 2

Eliquis

Bristol-Myers Squibb

Preclinical

3 3

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

2 4

Nolvadex

AstraZeneca

Preclinical

1 5

Oncovin

EEastern Cooperative Oncology Group

Preclinical

8 6

Intron a

Merck & Co.

Preclinical

—7

Smac Mimetic LCL161

MM.D. Anderson Cancer Center

Phase 2

1 8

Oblimersen Sodium

NNational Cancer Institute (NCI)

Preclinical

2 9

Florbetaben

LLife Molecular Imaging GmbH

Preclinical

1 10

Chemotherapy Drug

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Primary Myelofibrosis1 trial

LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT02098161·50 enrolled

Multiple Myeloma1 trial

SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple Myeloma

Completed·MMayo Clinic·Phase 2·NCT01955434·25 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Smac Mimetic LCL161. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Smac Mimetic LCL161 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Smac Mimetic LCL161. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — M.D. Anderson Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MM.D. Anderson Cancer Center

Smac Mimetic LCL161

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Primary Myelofibrosis1 trial

Multiple Myeloma1 trial

References

Drug Info

Quick Facts

Related News